Asia Pacific Glioblastoma Multiforme Treatment Market Size & Outlook
Asia Pacific glioblastoma multiforme treatment market, 2018-2030 (US$M)
Related Markets
Asia Pacific glioblastoma multiforme treatment market highlights
- The Asia Pacific glioblastoma multiforme treatment market generated a revenue of USD 551.4 million in 2023.
- The market is expected to grow at a CAGR of -59.4% from 2024 to 2030.
- In terms of segment, hospitals was the largest revenue generating end-use in 2023.
- Hospitals is the most lucrative end-use segment registering the fastest growth during the forecast period.
Asia Pacific data book summary
| Market revenue in 2023 | USD 551.4 million |
| Market revenue in 2030 | USD 1.0 million |
| Growth rate | -59.4% (CAGR from 2023 to 2030) |
| Largest segment | Hospitals |
| Fastest growing segment | Hospitals |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hospitals |
| Key market players worldwide | Merck & Co Inc, Amgen Inc, Roche, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries, Arbor Pharmaceuticals, Amneal Pharmaceuticals, Karyopharm Therapeutics Inc, Sumitomo Dainippon Pharma Oncology |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 36.4% of the global glioblastoma multiforme treatment market in 2023.
- Globally, Latin America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 2.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Glioblastoma Multiforme Treatment Market Scope
Glioblastoma Multiforme Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific glioblastoma multiforme treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.
Hospitals was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Asia Pacific glioblastoma multiforme treatment market based on hospitals covering the revenue growth of each sub-segment from 2018 to 2030.
GBM is less common in Asia Pacific countries, which reflects disparities in genetics, diagnosis, healthcare infrastructure, and reporting practices. The treatment modalities are the same as practiced in other countries surgery followed by radiation and chemotherapy. However, the output differs considering the economy and health insurance coverage of countries.
Asia Pacific is expected to be the fastest-growing glioblastoma multiforme (GBM) treatment market owing to various factors such as entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in healthcare sector.
Reasons to subscribe to Asia Pacific glioblastoma multiforme treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific glioblastoma multiforme treatment market databook
-
Our clientele includes a mix of glioblastoma multiforme treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific glioblastoma multiforme treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific glioblastoma multiforme treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific glioblastoma multiforme treatment market
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
